<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836757</url>
  </required_header>
  <id_info>
    <org_study_id>msm2012</org_study_id>
    <nct_id>NCT01836757</nct_id>
  </id_info>
  <brief_title>Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage</brief_title>
  <acronym>msm</acronym>
  <official_title>The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.Papanikolaou Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G.Papanikolaou Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To delineate the effect of MSM on osteoarthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design:
      Randomized, double-blind, placebo-controlled trial including an intervention and a placebo
      group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups.
      Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and
      placebo for the other. Outcomes measured are the Western Ontario and McMaster University
      Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and
      SF-36 (overall health-related quality of life).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with improved Mobility</measure>
    <time_frame>26 weeks</time_frame>
    <description>Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>26 weeks</time_frame>
    <description>On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>MSM group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 3 gr twice a day for 26 weeks (6 gr/day total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MethylSulfonylMethane (MSM)</intervention_name>
    <description>Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)</description>
    <arm_group_label>MSM group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Knee and hip OA

          -  men and women &gt;45 years of age

        Exclusion Criteria:

          -  any other type of arthritis

          -  chronic pain syndrome

          -  arthroscopic surgery in the past 8 months

          -  intra-articular corticosteroidsin the past 8 months

          -  hyaluronic acid injections in the past 8 months

          -  narcotic pain killers use

          -  renal or hepatic disease

          -  body mass index (BMI) &gt;45 kg/m2

          -  cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pagonis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle's University of Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Pagonis, MD, PhD</last_name>
    <phone>00306980488686</phone>
    <email>iatros1@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>G. Papanikolaou Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis Givisis, MD, PhD</last_name>
      <phone>00306945264010</phone>
    </contact>
    <investigator>
      <last_name>Thomas Pagonis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G.Papanikolaou Research Group</investigator_affiliation>
    <investigator_full_name>Thomas Pagonis</investigator_full_name>
    <investigator_title>Orthopaedic Surgeon</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>CAM treatments</keyword>
  <keyword>MSM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl sulfone</mesh_term>
    <mesh_term>Dimethyl Sulfoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

